43E0.F electroCore, Inc.
- Market cap
- EUR 61.8M
- P/E
- -
- P/B
- 33.55x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 43E0.F undervalued?
Graham numberThe Graham number of electroCore, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
electroCore, Inc. fundamental analysis
No fundamental analysis for electroCore, Inc. yet.
electroCore, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About electroCore, Inc.
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and parox…
Full company profileelectroCore, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
electroCore, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 5.45M | 8.59M | 16.0M | 25.2M | 32.0M | 38.3M |
| Gross Profit | 4.07M | 6.98M | 13.2M | 21.4M | 27.8M | 33.5M |
| Operating Income | -20.0M | -22.9M | -19.3M | -12.2M | -13.2M | -12.9M |
| EBITDA | - | -22.3M | -18.2M | -10.3M | -11.7M | -12.0M |
| Net Income | -17.2M | -22.2M | -18.8M | -11.9M | -14.0M | -12.9M |
| EPS | -3.65 | -4.67 | -3.14 | -1.79 | -1.74 | -1.41 |
| Balance Sheet | ||||||
| Total Assets | 42.8M | 24.8M | 16.1M | 20.5M | 18.7M | 17.3M |
| Total Liabilities | 6.19M | 7.67M | 8.66M | 12.9M | 20.4M | 19.8M |
| Shareholders' Equity | 36.6M | 17.1M | 7.44M | 7.54M | -1.71M | -2.51M |
| Cash & Short-term Investments | 34.7M | 17.7M | 10.3M | 3.45M | 7.04M | 6.31M |
| Cash Flow | ||||||
| Operating Cash Flow | -13.6M | -16.6M | -14.7M | -6.95M | -8.19M | -12.5M |
| Capital Expenditure | 0.00 | 0.00 | 206K | 0.00 | 66.0K | 8.00K |
| Free Cash Flow | -13.6M | -16.6M | -14.9M | -6.95M | -8.25M | -12.5M |
| Ratios | ||||||
| ROE | -47.0% | -129.7% | -253.1% | -157.6% | - | - |
| ROA | -40.2% | -89.5% | -117.0% | -58.1% | -74.8% | -74.7% |
| Net Profit Margin | -315.9% | -257.9% | -117.5% | -47.2% | -43.6% | -33.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
electroCore, Inc. dividends
electroCore, Inc. has not paid dividends in the last 5 fiscal years.
Who owns electroCore, Inc.
- Insiders 34.19%
- Institutions 11.95%
- Public & others 53.87%
- Shares outstanding 9.23M
- Free float 5.98M
electroCore, Inc. company profile
- Company name
- electroCore, Inc.
- Ticker
- 43E0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 83
- Fiscal year end
- December
- Address
- 200 Forge Way, Rockaway, NJ, United States, 07866
- Phone
- 888 903 2673
- Website
- electrocore.com
About electroCore, Inc.
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
electroCore, Inc. management
7- Dr. Thomas J. Errico M.D.Founder & Independent Chairman · born 1952
- Mr. Joshua S. LevCFO, Interim CEO, President & Director · born 1984
- Mr. Michael FoxCOO, Interim CEO, Interim President & Director · born 1967
- Ms. Jennifer A. HayesVice President of HR & Employee Success
- Dr. Peter S. Staats M.B.A., M.D.Chief Medical Officer · born 1964
- Ms. Amanda YanuklisChief of Staff
- Mr. Andy BrownVice President & Corporate Controller